Table 1.
Selected studies of BPA with hemodynamic and other outcomes (since 2017)
| Study | N, population | mPAP, mmHg | PVR, WU | CI, L/min/m2 | 6MWD, m | WHO FC |
|---|---|---|---|---|---|---|
| Aoki (2017) (Japan) | N=424, before and 6 months after BPA | 38 ± 10 to 25 ± 6 | 7.3 ± 3.2 to 3.8 ± 1 | 2.7 ± 0.1 to 2.5 ± 0.5 | 380 ± 138 to 486 ± 112 | Pre-BPA 28%; not reported post-BPA |
| Ogawa (2017) (Japan) | N=308, before and immediately after BPA. | 43.2 ± 11 to 24.3 ± 6.4 | 10.6 ± 5.6 to 4.5 ± 2.8 | 2.6 ± 0.8 to 2.9 ± 0.7 | 318.1 ± 122.1 to 401.3 ± 104.8 | Median FC: 3 to 2 |
| Olsson (2017) (Germany) | N=56, before and 24 weeks after BPA | 40 ± 12 to 33 ± 11 | 7.4 ± 3.6 to 5.5 ± 3.5 | 2.4 ± 0.6 to 2.5 ± 0.6 | 358 ± 108 to 391 ± 108 | % of pts in WHO III/IV: 84% to 29% |
| Darocha (2017) (Poland) | N=22, before and immediately after BPA | 51.7 ± 10.6 to 35 ± 9.1 | 10.4 ± 3.9 to 5.5 ± 2.2 | 2.2 ± 0.5 to 2.5 ± 0.4 | 323 ± 135 to 410 ± 109 | % of pts in WHO III/IV: 96% to 20% |
| Kriechbaum (2018) (Germany) | N=51, before and 6 months after BPA | 39.5 ± 12.1 to 32.6 ± 12.6 | 6.4 ± 2.7 to 5 ± 2.3 | 2.5 ± 0.6 to 2.5 ± 0.5* | 375 to 308.5 | % of pts in WHO III/IV: 96% to 12% |
| Brenot (2019) (France) | N=79 from more recent period; before and 3-6 months after BPA | 43.6 ± 9.1 to 29.5 ± 7.7 | 7.5 ± 3 to 3.6 ± 2 | 2.73 ± 0.62 to 3.18 ± 0.68 | 407 ± 103 to 449 ± 86 | % of pts in WHO III/IV: 55.1% to 8% |
| Hoole (2020) (UK) | N=30, before and 3 months after BPA | 44.7 ± 11 to 34.4 ± 8.3 | 8.3 ± 3.5 to 5.5 ± 2.5 | CO: 4.4 ± 1.1 to 4.8 ± 1.1 | 366 ± 107 to 440 ± 94 | % of pts in WHO III/IV: 80% to 13% |
*Not statistically significant. Abbreviations: mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, WU Wood units, CI cardiac index, 6MWD 6-min walk distance, WHO World Health Organization, FC functional class, CO cardiac output